CTRI

T2DM can be a long-term condition that requires extended blood sugar management: the combined approaches such as pharmacological, physical and, in recent years, therapeutic interventions directed at the microbiome are the most effective in managing it (Diagnosis and Classification of Diabetes Mellitus, 2013). While standard formulations which include insulin, metformin and SGLT2 inhibitors assist patients to manage their blood glucose levels, they rarely come without a fair share of side effects such as hypoglycemia, weight gain or gastrointestinal problems (Wilcox et al., 2020). They do not, however, resolve the underlying problems that lead to insulin resistance and Î²-cell dysfunction. For this reason, there has been a growing need to look for new and safer, and combined therapies that help not only control hyperglycemia but also treat underlying conditions, the imbalanced metabolic state (Cerf, 2013).The enzyme blend GlucoSEB PB can be a part of diabetic care regimen. The enzymes modulate carbohydrate metabolism while probiotics support in improving gut health. Numerous studies have reported that the gut microflora is closely related to body metabolism. An imbalance of intestinal microbiota, or dysbiosis, is one characteristic of T2DM that leads to metabolic dysregulation by causing insulin resistance, systemic inflammation and increased gut permeability (Hou et al., 2022; Wu et al., 2023; Xia et al., 2021). GlucoSEB PB consists of components that have gut microbiome targeted mechanisms primarily focused on enhancing metabolic parameters in patients with diabetes rather than solely targeting dysglycemia. The aim of evaluating GlucoSEB PB is described as follows: ï‚· Metabolic Health: The enzyme blend is useful in decreasing the glycemic index of consumed carbohydrates by controlling the free glucose into the bloodstream, thus lowering blood glucose levels after a meal. This might have special significance in avoiding glucose toxicity which is one of the factors that lead to insulin resistance. The manufacture of prebiotic fibers also helps in metabolic health by altering the gut microbiota which may increase insulin sensitivity and decrease systemic inflammation levels. ï‚· Gut Microbiome Modulation: Since there is a wealth of data associating gut dysbiosis and T2DM; promoting good gut bacteria through GlucoSEB PB is of particular interest. There are studies that support the use of Probiotics as adjunct therapy for blood sugar control and those that reduce inflammation and improve metabolic disease. Since GlucoSEB PB may promote a healthier microbiome, it may also have a wider effect on metabolic health other than dysglycemia. GlucoSEB PB treatment combines the benefits of targeting metabolic and gut health to diminish the ill effects caused due to diabetes. GlucoSEB PB is an advanced therapy that promises new avenues aimed at diabetes management.